Vascular-targeting agent
A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.[1]
VTAs can be small-molecule or ligand-based.
Small-molecule VTAs include:
- microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
- vadimezan (ASA404)
Clinical trials
Phase II : ZD6126, CA4P, plinabulin (NPI-2358)[2][3][4]
Phase III : DMXAA (ASA404).
References
- ↑ "Vascular Targeting Agents as Cancer Therapeutics" (PDF). 2004.
- ↑ "NPI-2358". clinicaltrials.gov.
- ↑ Monica M. Mita; et al. (2010). "Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas". Clin Cancer Res. 16 (23): 5892–5899. doi:10.1158/1078-0432.CCR-10-1096. PMID 21138873.
- ↑ Staff (2009). "Clinical Trials Update". Genetic Engineering & Biotechnology News. 29 (8): 58.
This article is issued from Wikipedia - version of the 9/2/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.